ESALY News and Press, Eisai Co. Ltd. ADR From 01/07/23

The US FDA on Friday granted accelerated approval to Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALY ) Leqembi (lecanemab), just the second biologic medicine ever approved for Alzheimer's disease. The therapy is expected to become available around the week of Jan. 23. It com...

Eisai's Commitment to Scientific Evidence and Patient Safety PR Newswire Hope for Patients with Early Alzheimer's Disease TOKYO , Jan. 6, 2023 /PRNewswire/ -- LEQEMBI™ (lecanemab-rimb) has the potential to make a difference for people livin...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips One stock that’s trading in the right direction today is prominent mega-cap biotech stock  Biogen  (NASDAQ: BIIB ). Shares of BIIB stock have surged around 3.7% as of early afternoon trading on apparent hopes...

Biogen ( NASDAQ: BIIB ) is separating its research and development department into two separate units , a day before the US FDA is set to act on its application for Alzheimer's therapy lecanemab. Priya Singhal, currently Head of Global Safety and Regulatory Sciences and interim He...

Summary Lecanemab only significantly slows down the progression of Alzheimer's disease in APOE4 carriers. Lecanemab is suspected of causing at least three deaths. The FDA may still grant approval to lecanemab with a warning label regarding brain bleeds and brain swelling. Medica...

Summary Today, we put Acumen Pharmaceuticals in the spotlight for the first time. The stock of this Alzheimer's focused developmental concern is trading near its net cash on the balance sheet. An investment analysis follows in the paragraphs below. For further ...

EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA PR Newswire TOKYO and CAMBRIDGE, Mass. , Dec. 22, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarte...

Astellas Pharma ( OTCPK:ALPMF ), Eisai ( OTCPK:ESALY ), Daiichi Sankyo ( OTCPK:DSKYF ), and Takeda Pharmaceutical ( OTCPK:TKPHF ) have agreed the collaboration to reduce environmental burden in the field of pharmaceutical packaging. Per the terms, the four firms will aim t...

Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...

Catalyst Pharmaceuticals ( NASDAQ: CPRX ) will acquire the U.S. rights to Eisai's ( OTCPK:ESALY ) epilepsy drug Fycompa (perampanel) as well as a period to review and negotiate the acquisition of a rare epilepsy asset in the Japanese drugmaker's pipeline. Terms calls for Eisai (...